SV Health Investors
Venture Capital, Other
Active
London, United Kingdom
320
22M
170
10.32
50
0.47
76
- Stages of investment
- Areas of investment
Summary
SV Health Investors appeared to be the VC, which was created in 1993. The main office of represented VC is situated in the Boston. The venture was found in North America in United States.
We can highlight the next thriving fund investment areas, such as Biopharma, Medical. Among the most popular portfolio startups of the fund, we may highlight EBR Systems, AcuFocus, Schweiger Dermatology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The overall number of key employees were 7.
When the investment is from SV Health Investors the average startup value is 10-50 millions dollars. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2015. Comparing to the other companies, this SV Health Investors performs on 12 percentage points less the average number of lead investments. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the SV Health Investors, startups are often financed by Split Rock Partners, Polaris Partners, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are Split Rock Partners, Novartis Venture Fund, DeNovo Ventures. In the next rounds fund is usually obtained by OrbiMed, Novo Holdings, Clarus Ventures.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 320
- Lead investments
- 50
- Exits
- 76
- Rounds per year
- 10.32
- Follow on index
- 0.47
- Investments by industry
- Health Care (217)
- Biotechnology (216)
- Medical Device (122)
- Medical (110)
- Therapeutics (76) Show 72 more
- Investments by region
-
- United States (253)
- United Kingdom (45)
- Switzerland (7)
- Austria (5)
- Ireland (1) Show 5 more
- Peak activity year
- 2016
- Number of Unicorns
- 4
- Number of Decacorns
- 4
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 17
- Avg. valuation at time of investment
- 166M
- Group Appearance index
- 0.75
- Avg. company exit year
- 12
- Avg. multiplicator
- 5.52
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Brixton Biosciences | 14 May 2024 | Biotechnology, Information Technology, Life Science | Early Stage Venture | 33M | United States, Massachusetts, Cambridge |
Pulmocide | 06 Dec 2022 | Biotechnology, Drug Discovery, Pharmaceuticals, Health Care, Health Diagnostics, Medical Device, Medical | Late Stage Venture | 52M | England, London, United Kingdom |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.